Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

Summary

Objectives: Primary objectives: To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors. To determine the overall tumor response rate to imatinib mesylate in combination with capecitabine and dacarbazine as first line and second line therapy in advanced metastatic medullary thyroid carcinoma. To determine the tolerability (toxicity) of this regimen. Secondary objectives: To determine the median overall survival (OS) and time to progression (TTP) for patients treated with this combination.

Timeline

Start

2004-12

Primary completion

2006-11

Completion

2013-08

Outcome

Outcome not reported

Stopped: “Study closed following Phase I portion, insufficient activity to continue to Phase II.”

Publications

• Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014 Aug 2;14:561. doi: 10.1186/1471-2407-14-561.

Drugs

Indications